Specific chromosomal translocations are associated with a number of hematologic malignancies. Several of these have been demonstrated to result in the activation of an oncogene. In lymphomas with the t(14;18) translocation, the bcl-2 gene is activated after translocation to the immunoglobulin locus. The goals of this project are to establish the mechanisms of the activation of the bcl-2 gene in human lymphomas and thus to develop a better understanding of the mechanisms of malignant transformation. A. Identification of the molecular mechanisms of transcriptional control of the bcl-2 gene during normal B-cell development and activation. In vivo footprinting and in vitro protein-DNA binding studies will be used to determine how the bcl-2 gene is regulated. B. Identification of the molecular mechanisms of transcriptional control of the translocated bcl-2 gene in t(14;18) lymphomas. Pulsed field electrophoresis will be used to separate the translocated from the normal allele and differences in the binding of transcriptional regulatory factors will be identified by genomic footprinting. C. Identification of differences in methylation at the bcl-2 loci in t(14;18) lymphomas. Methylation of cytosine residues in the regulatory regions of each allele will be studied. D. Effect on bcl-2 expression of mutations identified in the regulatory regions. Sequence information will be acquired, and mutations that occur with a high frequency will be examined for their effects on the binding of regulatory proteins. E. Identification of the mechanisms of transcriptional control of bcl-2 in the 5' translocations found in CLL and comparison to those operative in the t(14;18) lymphomas. In vivo footprinting studies will be performed on both the translocated and normal alleles in CLL cells after separation of the two by electrophoresis. F. Development of a model system to test hypotheses for the mechanisms of bcl-2 activation. A model system will be used to determine whether the results of the in vivo studies can be reproduced in a system that leads to bcl-2 deregulation; this will also be used to determine which elements are required for deregulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA056764-01A2
Application #
3201167
Study Section
Pathology B Study Section (PTHB)
Project Start
1993-08-01
Project End
1997-05-31
Budget Start
1993-08-01
Budget End
1994-05-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Xiang, H; Noonan, E J; Wang, J et al. (2011) The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells. Leukemia 25:1484-93
Duan, H; Heckman, C A; Boxer, L M (2007) The immunoglobulin heavy-chain gene 3'enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 26:2635-41
Xiang, Hong; Wang, Jinghong; Boxer, Linda M (2006) Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol 26:8599-606
Heckman, Caroline A; Wheeler, Melissa A; Boxer, Linda M (2003) Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22:7891-9
Heckman, Caroline A; Cao, Thai; Somsouk, Lina et al. (2003) Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 63:6666-73
Zheng, Z; Venkatapathy, S; Rao, G et al. (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16:2429-37
Heckman, Caroline A; Mehew, John W; Boxer, Linda M (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898-908
Arcinas, M; Heckman, C A; Mehew, J W et al. (2001) Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res 61:5202-6
Wu , Y; Mehew, J W; Heckman, C A et al. (2001) Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240-51
Heckman, C A; Mehew, J W; Ying, G G et al. (2000) A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 275:6499-508

Showing the most recent 10 out of 17 publications